Trading Alert - Family Room Entertainment Coming to a Theater Near You

November 1, 2002
Volume V, Issue 83
Email :

To OTC Journal Members:

The investment community loves biotech companies because the upside potential is enormous. Biotech companies may spend years and hundreds of millions of dollars developing exciting new drugs and therapies. Along the way, the market begins assigning a value to the company as progress is made. As a biotech companies moves through the various studies and clinical trials of a new drug, both positive and negative results drive the stock up and down. Successful new drug introductions can yield billions in profits over the long term.

Long before the company generates revenues from a new drug the market has assigned a value. The market was willing to drive the price of Immclone (NASDAQ: IMCL) up to $75 as early results from its new cancer drug Erbitux were promising. Once the FDA determined early studies were flawed, the stock dropped below 10% of its previous high. Now, the stock is beginning to trade up again as the company has submitted new trial plans, in partnership with Bristol Myers, to the FDA.

Today's idea is tailored made for the same investors who like the risk oriented upside of a biotech idea. However, we love this one because it has the upside potential of a biotech company without most of the downside risk. Over the next five years this company could enjoy millions of dollars in profits off properties it is developing right now without spending hundreds of millions of dollars to get there. They are doing it with other people's money, and they have two potential blockbuster products coming to a theater near you between now and the end of this year, which is why you need to act today. Very few investors know about this company, but that will change over the next three months as millions of potential investors go to the theater and see their new movies.

For your review:

Trading Alert- Family Room Entertainment (OTC BB: FMLY)

Family Room Entertainment develops, produces and performs production related services for the entertainment industry mainly through its wholly owned subsidiary Emmett/Furla Films Productions Corporation. Primarily, it's a film production company. Family Room also has a music and theater division.

After three years of proving themselves to the movie industry, wholly owned subsidiary Emmet/Furla Productions has its first two major theatrical releases coming to theaters between now and the end of the year. Half Past Dead, staring Steven Seagal and Nia Peeples, and rapper JaRule, premiers on November 15th.

Their second movie, Narc, starring Ray Liotta and Jason Patric, has been coproduced by Tom Cruise. There is best actor Oscar buzz associated with Ray Liotta on this film. It is scheduled to premier in theaters on December 20th.

Family Room has been producing and coproducing movies for three years, and has finally made a successful transition to the big time with these major films.

Today, just after the market closed, Family Room announced the completion of the filming of their second Seagal feature, Out For A Kill, and the signing of Val Kilmer to play the lead role in the upcoming feature they will produce entitled Blind Horizon. Evidence is building of this company's potential as they continue to fill their pipeline with properties.

Business Model- BioTech Upside Without the Risk

Millions of dollars are made in Hollywood from successful movies. Hundreds of millions of dollars are made from successful franchise movie series- i.e. Austin Powers, Star Wars, Harry Potter, etc.

The movie industry has two major segments- Production and Distribution. Distribution requires enormous capital expenditure, and is handled by the major names like Paramount, Warner Brothers, MGM, and Sony.

The production process requires the funding of the hard costs associated with making a film, which include actors salaries, crew, location, etc. Emmett/Furla Productions, the wholly owned subsidiary of Family Room, is an independent producer which obtains financing for the hard costs of production, and then retains anywhere from 10% to 50% of the profits throughout the life of a film. Therefore, a successful movie can provide cash flow and profits for years after the movie is released, with the first real moneys coming in about 15 months after hitting the box office.

Over the past three years, Emmett/Furla has developed a reputation for getting big name actors recruited, and delivering a movie on budget and on time. Therefore, demand is increasing for their services. In order to achieve this reputation, they spent three years producing the following list of films, most of which went straight to content hungry cable:

Run For the Money Christian Slater, Val Kilmer, Daryl Hannah
Speedway Junky Johnathan Tayor Thomas, Tiffani Amber Thiessen
Held For Ransom Dennis Hopper
After Sex Brooke Shields
I'm Over Here Now Andrew "Dice" Clay
Good Advice Charlie Sheen, Denise Richards, and Angie Harmon (Sheen and Richards met on this fill and got married)
The Badge Billy Bob Thorton, Patricia Arquette
Ticker Steven Seagal, Tom Sizemore
Try 17 Elijah Wood, Mandy Moore
Shottas Ky-Mani Marley, Spragga Benz

With the exception of Speedway Junky, Try 17, and Shottas all of these films went directly to cable. These films allowed Emmett/Furla to establish a reputation for delivering films on time and on budget.

Speedway Junky, Held For Ransom, and After Sex could begin to spin out residual revenues for Emmet/Furla in 2003. Money will flow in with no cost associated. Amounts could range from $250,000 to $2 million over the life of each film. This money will be bio-tech like profits, as all the costs have already been defrayed. However, these have minimal potential as compared to the two movies coming out later this year.

Emmett/Furla has made the transition to the big time with this year's upcoming releases and projects in the pipeline. Here are quick overviews of the two due out this year:

Half Past Dead

Half Past Dead, starring Steven Seagal and popular rapper JaRule, premiers in movie theaters on November 15th. In this movie a criminal (Morris Chestnut) tries to sneak into a high tech, futurist prison at Alcatraz. His intent- to find out where death row inmate has hidden $200 million worth of gold. Just click on the logo to visit the film's web site.

The plan is sabotaged by undercover FBI agent Steven Seagal. This movie is already being heavily promoted on billboards, buses, and TV nationwide. We first saw a TV ad during the seventh game of the World Series.

Seagal's action films have a long history of profitability. His 2001 film, entitled Exit Wounds, featured rapper DMX, which expands the demographic target audience significantly. The film cost $33 million to produce, and did $18.5 million at the box office opening weekend. The film grossed $52 million before going to DVD and subsequently to cable, where the real profits are made.

Seagal's action films have a history of commercial success. Under Siege, which premiered in 1992, cost $12 million to produce. The film did $14.5 million opening weekend, eventually grossed $73 million, and has since generated $154 million worldwide and $37 million in rental fees.


NARC, starring Ray Liotta and Jason Patrick is scheduled to debut in theaters on December 20th. According to the NY Post: "Ray Liotta gives his strongest performance since "GoodFellas" as a dirty Detroit cop who recruits a disgraced narcotics officer (Jason Patric) to hunt down his partner's killer. Joe Carnahan's gritty indie makes the similar "Training Day" look like a Disney flick by comparison." Just click on the logo to visit the film's web site.

Produced for a mere $7.5 million budget, this movie promises to be one of the biggest box office successes of 2002. Ray Liotta is being talked about for an Oscar nomination for his performance.

This movie met with tremendous critical acclaim at the Sundance Film Festival. Lion's Gate, which had acquired the distribution rights when the film was in its infancy, sold part of its rights to Paramount.

Emmett/Furla coproduced this movie along with Tom Cruise's Cruise/Wagner productions. This movie has the potential to be a box office blockbuster and huge money maker.

Market Valuation and Upside Potential

Family Room closed today at $.40. With approximately 19 million shares issued and outstanding, the market value of the entire company is only $7.6 million.

In mid 2001, the stock was hot for a brief period, and traded to nearly $2 on the heels of announcements concerning upcoming projects.

Volume has been picking up in the stock recently as investors are starting to understand the potential magnitude of the upcoming major theatrical releases for Family Room's future bottom line. Today, the stock traded the highest volume it has this year, posting 478,000 shares of volume. Fortunately for our subscribers, the stock did not move up dramatically in price.

Like a biotech company, their products are finally finding their way to the market. Unlike a biotech company, they didn't have to spend $2 billion to get to this point.

This stock should now begin to trade more efficiently as these movies become commercially successful. In the meantime, Emmett/Furla productions is already on to other projects.

Today, just after the market closed, Family Room announced they just completed the filming of another Steven Seagal movie slated for release in the Spring, and signed Val Kilmer to play the starring role in upcoming thriller "Blind Horizon".

As more film properties get released, Family Room's potential for windfall profits grows dramatically. Unlike other independent production companies, Family Room's annual overhead is minuscule. Cochairmen Randall Emmett and George Furla don't even take salaries out of the company. They take income out of production budgets which are financed with other people's money.

If one of their projects develops into a franchise film series the company could enjoy hundreds of millions in profits. Their relationship with Steven Seagal holds that promise, just as the Chuck Norris character in the Missing in Action series, Sylvester Stallone in Rocky and Rambo, and many others did in the past.

We can easily see this company with a $25 million market cap this year as these new films hit the box office. This would put the stock at $1.30. A more realistic short term target would be $.80 to $.90 as investors catch on to Family Room. Allow at least 30 days for this stock to pick up steam. In the interim, a 20% stop loss would be prudent if the market trades against us.

Go to the theaters and see their upcoming films. Decide for yourself if you feel this company is on the verge of a major break out.

Here is the complete text of today's news release for your review:

Press Release Source: Emmett/Furla Films

Family Room Finishes Going ``Out for a Kill'' and Sees the ``Blind Horizon''

Friday November 1, 4:15 pm ET 

LOS ANGELES--(BUSINESS WIRE)--Nov. 1, 2002--Emmett/Furla Films, a wholly owned subsidiary of Family Room Entertainment Corporation (OTCBB:FMLY - News) is pleased to announce the completion of principal photography on "Out for a Kill" as well as announcing that Val Kilmer has committed to the lead role in their forthcoming production, "Blind Horizon." 
"Out for a Kill," an action picture set within the backdrop of the drug wars, is written by Dennis Dimster-Denk. Michael Oblowitz is set to direct this picture. "Out for a Kill", was originally announced on May 20, 2002, when "Daily Variety" reported: "Actor-producer Steven Segal has launched a production and sales company, Luminosity Media. He will produce and star in its first two projects in conjunction with Millennium/Nu Image. The pictures are `Belly of the Beast' and `Out for a Kill.'" 

In the picture "Blind Horizon", Val Kilmer has agreed to play "Frank," a gunshot amnesia victim who warns a small town sheriff about an assassination plot against the President during his campaign tour, and must uncover a conspiracy and his role in the plot. The screenplay was written by F. Paul Benz and Steve Tomlin. Newman/Tooley's Vincent Newman and Tucker Tooley as well as Emmett/Furla's Randall Emmett and George Furla will produce the picture. Chris Bender and J.C. Spink are also attached as co-executive producers. Michael Haussman is set to direct. 

Haussman, who hails from the world of commercials and music videos, has garnered attention for his spots for Levi's, Dockers, and Phillips, as well as his music videos, such as Madonna's "Take a Bow." He is also attached to direct "Takedown" for Jerry Bruckheimer Productions and Disney. 

Principal photography for "Blind Horizon" is scheduled to commence in December in New Mexico. The picture is being funded in conjunction with New Mexico's Film Investment Program. 

Forward Looking Statement: 

Safe Harbor: Statements contained in this news release which are not historical facts are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties, which could cause results to differ materially from those projected. 

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "ACT"). In particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "expect," "intend to" and similar conditional expressions are intended to identify forward- looking statements within the meaning of the ACT and are subject to risks and uncertainties, and actual results could differ materially from those expressed in any forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financings and other risks.

     Emmett/Furla Films, Los Angeles
     M. Dal Walton, III, 323/850-2868
Source: Emmett/Furla Films

Charts Provided Courtesy Of

The OTC Journal is a proud partner of the Online Investment Community. A next generation Online Analyst Exchange providing Members the ability to search, review, track and monitor some of the Internet's best Online CAs (CyberAnalysts). Members have the opportunity to potentially achieve higher returns by viewing top performing portfolios and receiving real-time alerts from favorite CAs. also has a lucrative incentive model for experienced investors and traders who consistently outperform the market. Share market ideas with other like-minded investors, establish a proven track record, provide insightful commentary, attract followers and ultimately become one of the Internet's highest paid and most sought after CyberAnalysts! 

Click here to receive your FREE 30-Day Trial Membership with no further obligation. Sign Up Today! 

The Newsletter is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features.  Likewise, this newsletter is owned by MarketByte, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication.

Click Here to view our compensation on every company we have ever covered, or visit the following web address: for our full profiles and for Trading Alerts. MarketByte LLC has been pledged a fee of $25,000 by Family Room Entertainment for coverage through January 31, 2003. An additional 150,000 free trading shares have been pledged by a third party. To date, $10,000 has been received directly from Family Room. Please review our policy on selling shares found in our mission statement on our home page.

All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which they are affiliated, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

The profiles, critiques, and other editorial content of the may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.


We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at Disclaimer ID:xG1jf4ll Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

Unsubscribe Here

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to


The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at and/or the National Association of Securities Dealers ("NASD") at We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of


You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to